Genzyme Corp

Genzyme — Merger or Acquisition (February 2011)

15 slides from Genzyme's merger presentation, Feb 16, 2011

  1. Slide 1: Adding a New Global Platform to our Sustainable Growth Strategy

    Adding a New Global Platform to our Sustainable Growth Strategy February 16, 2011

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their under

  3. Slide 3: Conference Call Speakers

    Conference Call Speakers sanofi-aventis Christopher A. Viehbacher Chief Executive Officer Jérôme Contamine Executive Vice President, Chief Financial Officer Genzyme Henri A. Termeer Chairman of the Board, President, Chief Executive Officer

  4. Slide 4: Rationale for sanofi-aventis

    Rationale for sanofi-aventis Christopher A. Viehbacher Chief Executive Officer

  5. Slide 5: Strategically Consistent and Financially Attractive Acquisition for sanofi-aventis

    A Strategically Consistent and Financially Attractive Acquisition for sanofi-aventis Creates a meaningful new growth platform Expands our footprint in biotechnology Increases our U.S. presence Bolts on to our existing business Significantly contributes to our goal of sustainable earnings growth Driv

  6. Slide 6: Rationale for Genzyme

    Rationale for Genzyme Henri A. Termeer Chairman of the Board, President, CEO

  7. Slide 7: The Right Transaction for Genzyme, its Shareholders, and Other Stakeholders

    The Right Transaction for Genzyme, its Shareholders, and Other Stakeholders Represents a new beginning for Genzyme Tremendous value recognized by sanofi-aventis in our record of innovation in our unique and pioneering approach to serving patients Shared exciting vision of the future in which Genzyme

  8. Slide 8: Transaction Overview

    Transaction Overview Jérôme Contamine Executive Vice President, Chief Financial Officer

  9. Slide 9: Sanofi-aventis to Acquire Genzyme

    Sanofi-aventis to Acquire Genzyme $74.00 per share in cash plus contingent value right (CVR) Risk / reward on Lemtrada™ and sustained production of Cerezyme® and Fabrazyme® shared through CVR structure CVR security to be publicly traded Transaction unanimously approved by both Boards of Directors No

  10. Slide 10: CVR Structure

    Production Milestone Approval Milestone Sales Milestone #1 Sales Milestone #2 Sales Milestone #3 Sales Milestone #4 Cash Payments Triggers Estimated Timing of Potential Payments CVR Structure (1) $1.00 per CVR $1.00 per CVR $2.00 per CVR $3.00 per CVR $4.00 per CVR $3.00 per CVR Paid if specified Ce

  11. Slide 11: Genzyme Acquisition Delivers Significant Financial Benefits

    Genzyme Acquisition Delivers Significant Financial Benefits Revenue growth acceleration Genzyme to benefit from sanofi-aventis’ extensive resources and experience in manufacturing Significant Business EPS accretion expected: Accretive in Year 1 after closing Accretion of € 0.75 to € 1.00 by (1) Valu

  12. Slide 12: Transaction valued at $20.1bn, excluding CVR component

    Transaction valued at $20.1bn , excluding CVR component Net cash position of Genzyme: ~$800m by end of Fully financed upfront cash transaction Bridge facilities ( $10bn to be refinanced by bond issuance and $5bn to be refinanced by cash flow) Cash and/or issuance of commercial paper Attractive cost

  13. Slide 13: Next Steps

    Next Steps Christopher A. Viehbacher Chief Executive Officer

  14. Slide 14: A Clear Path Forward given Antitrust Clearance already Granted in the U.S. and EU

    Legal process Tender offer, CVR registration Planning Integration A Clear Path Forward given Antitrust Clearance already Granted in the U.S. and EU Q1 Q2 Q3 Feb 16 Merger announcement Early Q2 Anticipated closing Mid Feb Kick-off Legal process Pre-integration process Integration process Day 1

  15. Slide 15: sanofi aventis

    sanofi aventis Because health macters

Genzyme — Merger or Acquisition (February 2011) on 6ix